Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious
than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee
and hip.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.